Dr. Rachel Tate
2 years 11 months ago
Prof Schett provides #ACR23 a wonderful, easy to digest, review of how CAR-T works. @RheumNow https://t.co/y5HZVAvvhy
Meral K. El Ramahi, MD MeralElRamahiMD
2 years 11 months ago
Dx: Idiopathic granulomatous mastitis
➡️median age: 30 yo
➡️usually 2yrs after breast feeding
➡️RF: hyperprolactinemia, leads to pro-inflam effect
➡️Extra-mammary manifestat: arthralgia, episcleritis, skin changes mimicking autoimm dz
➡️Tx: steroid + AZA vs MTX
#ACR23 @RheumNow https://t.co/lGT2UUIkoM
sheila
2 years 11 months ago
Some studies addressing fish oil supplementation in patients w/ SLE
Showed improvement in disease activity but not in serologic activity
#ACR23 @RheumNow https://t.co/ANf8yMUd1b
TheDaoIndex KDAO2011
2 years 11 months ago
Read my article on ACR Plenaries: Changing the Practice of Rheumatology #ACR23 @ACRheum @RheumNow @uptoTate @Yuz6Yusof @ericdeinmd
https://t.co/ql851dVzAk
Dr. Rachel Tate
2 years 11 months ago
What could CAR-T therapy mean for pts? Dr. Schett reviews 8 SLE pts, data collected since 2021 post 1 CAR-T treatment, & their marked improvement/remission of symptoms by classification criteria. Currently, he is studying a total of 15 pts (SLE, SS, myositis) #ACR23 @RheumNow https://t.co/MyMcF3PwiP
Mike Putman EBRheum
2 years 11 months ago
Excellent pragmatic RCT, TNF withdrawal in RA
Almost 2/3 flared by 1 yr; at 3 years up to 3 in 4
Supports my practice of generally continuing TNFs long term
Also highlights importance of pt preferences; 1 in 4 may do well if they wish to discontinue
@RheumNow #ACR23 #ACRBest https://t.co/G4l0DgBP2Z
Dr. Rachel Tate
2 years 11 months ago
Vaccination appears to be effective and safe post CAR-T treatment. This sets the stage for better understanding of the patient experience. Dr. Schett #ACR23 @RheumNow https://t.co/OQCNTt5wPh
TheDaoIndex KDAO2011
2 years 11 months ago
In case you missed it! Watch our ACR Monday Recap of the meeting with me, @RheumNow @EBRheum and @ericdeinmd. #ACR23 @uptoTate https://t.co/GpMdev0Yk7
Dr. Rachel Tate
2 years 11 months ago
#ACR23 Abs #2548 showed incidence rate of uveitis TEAEs was lower to Wk 16 in axSpA pts randomized to BKZ 160 mg Q4W vs PBO. https://t.co/kBLQnJbTU2 @rheumnow https://t.co/regYgvvCts
Dr. John Cush RheumNow
2 years 11 months ago
Bimekizumab is Coming… in 3rd Place
Nearly two dozen bimekizumab abstracts will be featured at #ACR23 and it recently received authorization in Europe and the US for psoriasis.
https://t.co/i2ptDnGr4a https://t.co/rZC6IORm5E
Dr. John Cush RheumNow
2 years 11 months ago
#ACR23 Daily Recap - MONDAY
Join our live-stream panel discussion as we dive deep into the highlights and key takeaways from day two of ACR 2023. https://t.co/0WXuV3wzzF
Over the years of navigating the annual meeting, I found the sessions with the most impact to my practice were the Plenary Sessions. During these sessions, the latest research is presented, new ideas are floated, and old myths debunked. Here are the top ACR2023 Plenary abstracts I found impactful for my practice.
Guidelines (ACR/EULAR/GRAPPA) for the management of psoriatic arthritis (PsA) recommend the early referral of patients with the suspected condition for early assessment and treatment. There remains a diagnostic delay of 1-2 years in PsA and ideally treatment should be commenced within 1 year of symptom onset.How early is early in PsA and is there a window of opportunity for treatment in PsA to ensure optimal outcomes?
Dr. John Cush RheumNow
2 years 11 months ago
ACR2023 Daily Recap - MONDAY
Join our live-stream panel discussion as we dive deep into the highlights and key takeaways from day two of ACR 2023. https://t.co/qOjSd8vuB3
